Skip to content
Olmesartan
Azor, Benicar, Tribenzor (olmesartan) is a small molecule pharmaceutical. Olmesartan was first approved as Benicar on 2002-04-25. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA. The pharmaceutical is active against type-1 angiotensin II receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
endocrine system diseasesD004700
Trade Name
FDA
EMA
Benicar (generic drugs available since 2016-10-26)
Combinations
Azor, Benicar, Tribenzor (generic drugs available since 2016-10-26)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amlodipine besylate
+
Hydrochlorothiazide
+
Olmesartan medoxomil
Tradename
Company
Number
Date
Products
TRIBENZORCosette Pharmaceuticals N-200175 RX2010-07-23
5 products, RLD, RS
Amlodipine besylate
+
Olmesartan medoxomil
Tradename
Company
Number
Date
Products
AZORCosette Pharmaceuticals N-022100 RX2007-09-26
4 products, RLD, RS
Hydrochlorothiazide
+
Olmesartan medoxomil
Tradename
Company
Number
Date
Products
BENICAR HCTCosette Pharmaceuticals N-021532 RX2003-06-05
3 products, RLD, RS
Olmesartan medoxomil
Tradename
Company
Number
Date
Products
BENICARCosette Pharmaceuticals N-021286 RX2002-04-25
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
azorNew Drug Application2022-06-17
benicarNew Drug Application2022-06-20
olmesartan medoxomilANDA2023-06-20
tribenzorNew Drug Application2022-06-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
diabetic nephropathiesEFO_0000401D003928—
heart failureEFO_0003144D006333I50
hypertensionEFO_0000537D006973I10
left ventricular dysfunction—D018487—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09CA08: Olmesartan medoxomil
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DA08: Olmesartan medoxomil and diuretics
— C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
— C09DB02: Olmesartan medoxomil and amlodipine
— C09DX: Angiotensin ii receptor blockers (arbs), other combinations
— C09DX03: Olmesartan medoxomil, amlodipine and hydrochlorothiazide
HCPCS
No data
Clinical
Clinical Trials
126 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I101715251057
Essential hypertensionD000075222I10—1225230
Healthy volunteers/patients—12—11—14
DyslipidemiasD050171HP_0003119——2226
Type 2 diabetes mellitusD003924EFO_0001360E11——32—5
Metabolic syndromeD024821EFO_0000195E88.81——21—3
Cardiovascular diseasesD002318EFO_0000319I98——12—3
Peripheral arterial diseaseD058729EFO_0004265———1—1
Coronary artery diseaseD003324I25.1———1—1
Drug interactionsD004347———1—1
Show 4 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic nephropathiesD003928EFO_0000401—12——3
HyperlipidemiasD006949EFO_0003774E78.5——1—12
Heart failureD006333EFO_0003144I50——2——2
ProteinuriaD011507HP_0000093R80——2——2
Covid-19D000086382U07.1——1——1
AtherosclerosisD050197EFO_0003914I25.1——1——1
Retinal diseasesD012164HP_0000479H35.9——1——1
Kidney diseasesD007674EFO_0003086N08——1——1
Renal insufficiencyD051437HP_0000083N19——1——1
Atrial fibrillationD001281EFO_0000275I48.0——1——1
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ischemic strokeD000083242—2———2
Coronary diseaseD003327—1———1
GlomerulonephritisD005921N05—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Therapeutic equivalencyD0138102————2
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyperaldosteronismD006929HP_0011736E26————11
Ambulatory blood pressure monitoringD018660————11
Vascular stiffnessD059289————11
ExerciseD015444EFO_0000483————11
Obstructive sleep apneaD020181EFO_0003918G47.33————11
Prediabetic stateD011236EFO_1001121R73.03————11
Glucose intoleranceD018149HP_0000833R73.03————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOLMESARTAN
INNolmesartan
Description
Olmesartan is a biphenylyltetrazole. It has a role as an antihypertensive agent and an angiotensin receptor antagonist.
Classification
Small molecule
Drug classangiotensin II receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Identifiers
PDB—
CAS-ID144689-24-7
RxCUI321064
ChEMBL IDCHEMBL1516
ChEBI ID48416
PubChem CID158781
DrugBankDB00275
UNII ID8W1IQP3U10 (ChemIDplus, GSRS)
Target
Agency Approved
AGTR1
AGTR1
Organism
Homo sapiens
Gene name
AGTR1
Gene synonyms
AGTR1A, AGTR1B, AT2R1, AT2R1B
NCBI Gene ID
185
Protein name
type-1 angiotensin II receptor
Protein synonyms
Angiotensin II type-1 receptor, AT1 receptor, AT1AR, AT1BR, type-1B angiotensin II receptor
Uniprot ID
Q8TBK4
Mouse ortholog
Agtr1b (11608)
type-1 angiotensin II receptor B (P29755)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,490 documents
View more details
Safety
Black-box Warning
Black-box warning for: Azor, Benicar, Olmesartan medoxomil, Tribenzor
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
22,667 adverse events reported
View more details